237 related articles for article (PubMed ID: 18708994)
1. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin.
Tsujimoto M; Kinoshita Y; Hirata S; Otagiri M; Ohtani H; Sawada Y
Ther Drug Monit; 2008 Oct; 30(5):576-82. PubMed ID: 18708994
[TBL] [Abstract][Full Text] [Related]
2. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin.
Sun H; Huang Y; Frassetto L; Benet LZ
Drug Metab Dispos; 2004 Nov; 32(11):1239-46. PubMed ID: 15286055
[TBL] [Abstract][Full Text] [Related]
3. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
[TBL] [Abstract][Full Text] [Related]
4. Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier.
Deguchi T; Isozaki K; Yousuke K; Terasaki T; Otagiri M
J Neurochem; 2006 Feb; 96(4):1051-9. PubMed ID: 16445853
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form.
Niwa T; Aiuchi T; Nakaya K; Emoto Y; Miyazaki T; Maeda K
Clin Nephrol; 1993 Feb; 39(2):92-6. PubMed ID: 8448924
[TBL] [Abstract][Full Text] [Related]
6. Effects of renal failure on drug transport and metabolism.
Sun H; Frassetto L; Benet LZ
Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
[TBL] [Abstract][Full Text] [Related]
7. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
Deguchi T; Ohtsuki S; Otagiri M; Takanaga H; Asaba H; Mori S; Terasaki T
Kidney Int; 2002 May; 61(5):1760-8. PubMed ID: 11967025
[TBL] [Abstract][Full Text] [Related]
8. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia.
Henderson SJ; Lindup WE
J Pharmacol Exp Ther; 1992 Oct; 263(1):54-60. PubMed ID: 1403803
[TBL] [Abstract][Full Text] [Related]
9. Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Tsujimoto M; Hatozaki D; Shima D; Yokota H; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2012 Dec; 16(6):580-7. PubMed ID: 23190519
[TBL] [Abstract][Full Text] [Related]
10. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure.
Niwa T
Semin Nephrol; 1996 May; 16(3):167-82. PubMed ID: 8734460
[TBL] [Abstract][Full Text] [Related]
11. Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat.
Tsutsumi Y; Deguchi T; Takano M; Takadate A; Lindup WE; Otagiri M
J Pharmacol Exp Ther; 2002 Nov; 303(2):880-7. PubMed ID: 12388676
[TBL] [Abstract][Full Text] [Related]
12. Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats.
Deguchi T; Kouno Y; Terasaki T; Takadate A; Otagiri M
Pharm Res; 2005 Apr; 22(4):619-27. PubMed ID: 15846470
[TBL] [Abstract][Full Text] [Related]
13. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
[TBL] [Abstract][Full Text] [Related]
14. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans.
Fujita K; Sugiura T; Okumura H; Umeda S; Nakamichi N; Watanabe Y; Suzuki H; Sunakawa Y; Shimada K; Kawara K; Sasaki Y; Kato Y
Pharm Res; 2014 Jan; 31(1):204-15. PubMed ID: 23921491
[TBL] [Abstract][Full Text] [Related]
15. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid.
Boumendil-Podevin EF; Podevin RA; Richet G
J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164
[TBL] [Abstract][Full Text] [Related]
16. Effect of macrolide antibiotics on uptake of digoxin into rat liver.
Ito S; Nasu R; Tsujimoto M; Murakami H; Ohtani H; Sawada Y
Biopharm Drug Dispos; 2007 Apr; 28(3):113-23. PubMed ID: 17253595
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma.
Huang Y; Sun H; Frassetto L; Benet LZ; Lin ET
Rapid Commun Mass Spectrom; 2006; 20(10):1611-4. PubMed ID: 16628600
[No Abstract] [Full Text] [Related]
18. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins.
Kong F; Pang X; Zhong K; Guo Z; Li X; Zhong D; Chen X
Drug Metab Dispos; 2017 Jun; 45(6):593-603. PubMed ID: 28314825
[TBL] [Abstract][Full Text] [Related]
19. Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.
Katsube Y; Tsujimoto M; Koide H; Ochiai M; Hojyo A; Ogawa K; Kambara K; Torii N; Shima D; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Cancer Chemother Pharmacol; 2017 Apr; 79(4):783-789. PubMed ID: 28314987
[TBL] [Abstract][Full Text] [Related]
20. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease.
Tsujimoto M; Sugimoto S; Nagatomo M; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2014 Apr; 18(2):174-80. PubMed ID: 24119207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
